PulseAugur
EN
LIVE 21:17:36
中文(ZH) 立方制药：控股子公司聚乙烯醇滴眼液药品注册申请获受理

Lifang Pharmaceutical subsidiary's eye drop application accepted

By PulseAugur Editorial · [1 sources] ·

Lifang Pharmaceutical's subsidiary, Hefei Norite Pharmaceutical, has received a "Notice of Acceptance" from China's National Medical Products Administration for its polyvinyl alcohol eye drops. These eye drops function as a lubricant to alleviate symptoms such as dry eyes, foreign body sensation, and eye fatigue. The announcement was made by 36Kr, which also noted other unrelated financial and market news. AI

RANK_REASON The item reports on a regulatory acceptance for a specific pharmaceutical product, which falls under the 'tool' category as it's not a frontier release or significant industry event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Lifang Pharmaceutical subsidiary's eye drop application accepted

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The item reports on a regulatory acceptance for a specific pharmaceutical product, which falls under the 'tool' category as it's not a frontier release or significant industry event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
67 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Cube Pharmaceuticals: Polyvinyl Alcohol Eye Drops Drug Registration Application of Subsidiary Accepted

    36氪获悉，立方制药公告，近日，公司控股子公司合肥诺瑞特制药有限公司收到国家药监局下发的聚乙烯醇滴眼液药品注册上市许可申请的《受理通知书》。聚乙烯醇滴眼液可作为一种润滑剂预防或治疗眼部干涩、异物感、眼疲劳等刺激症状或改善眼部的干燥症状。

RELATED TOPICS